据交易所数据显示，12月17日，冠科美博-A(APLM)盘中上涨5.28%，截至04:02，报16.95美元/股，成交 50.49万美元，总市值3637.73万美元。 资料显示，冠科美博有限公司是一家创新型生物科技公司,专注於探索及开发可能与其他治疗方案结合 的肿瘤疗法,以利用免疫系统和靶向特定分子信号通路来抑制癌症。鉴於公司在美国和中国两地均开展 业务,公司相信公司具备良好条件利用与东西方其他生物科技公司合作的优势。自2015年成立以来,在公 司经验丰富的管理团队领导下,凭藉对不断发展的癌症治疗领域的深入了解,公司已建立一条由十(10)种 专注於肿瘤学的候选药物组成(跨12个项目)的管线,其中五(5)种候选药物处於临床阶段。 本文源自：市场资讯 作者：行情君 财务数据显示，截至2023年12月31日，冠科美博-A收入总额-7160.4万美元，同比增长62.06%；归母净 利润-1.73亿美元，同比增长28.33%。 大事提醒： 3月28日，冠科美博-A2023财年年报归属股东应占溢利-1.726亿美元，同比增长28.33%，基本每股收 益-2.32美元。 ...

Core Insights - Apollomics Inc. has entered into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited to resolve litigation related to preferred share redemption claims before its merger with Maxpro Capital Acquisition Corporation in 2023 [1][2] Financial Summary - The settlement agreement requires Apollomics to pay a total of US$5 million in cash to TWVC, to be paid in installments over two years, along with approximately US$879,757.78 in legal expenses [2] - The original damages claimed by TWVC were approximately US$40 million, as disclosed in the Form 20-F filed in April 2025 [2] Company Overview - Apollomics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies that can be combined with other treatments to target specific molecular pathways and harness the immune system [3] - The company's lead program is vebreltinib (APL-101), a selective c-Met inhibitor for treating non-small cell lung cancer and other advanced tumors with c-Met alterations, currently in a Phase 2 multicohort clinical trial [3]

Core Points - Apollomics Inc. announced changes to its board of directors, including the resignation of Mr. Po-Jen Hsueh and the appointment of Dr. Ya-Chi (Claudia) Huang to fill the vacancy [1][2] - The current board now consists of seven members, with Dr. Huang also taking over Mr. Hsueh's roles on the Audit Committee and Nominating and Corporate Governance Committee [2] - Dr. Huang brings extensive experience in biotechnology investment and corporate governance, having previously worked at Maxpro Ventures and Diamond Biofund [3][4][5] Company Overview - Apollomics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies that leverage the immune system and target specific molecular pathways [7] - The company's lead program is vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 clinical trial for non-small cell lung cancer and other advanced tumors [7]

Core Points - Apollomics Inc. announced changes to its board of directors, with Mr. Po-Jen Hsueh resigning and Dr. Ya-Chi (Claudia) Huang appointed to fill the vacancy [1][2] - The current board now consists of seven members, including five independent directors [2] - Dr. Huang has extensive experience in biotechnology investment and corporate governance, previously serving in significant roles in the biopharmaceutical industry [3][4][5] Board Changes - Mr. Po-Jen Hsueh resigned from the board on November 16, 2025, with no disagreements reported [1] - Dr. Ya-Chi (Claudia) Huang was appointed to the board and will also serve on the Audit Committee and Nominating and Corporate Governance Committee [2] - The board now includes Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Dr. Huang [2] New Director's Background - Dr. Huang is currently the Assistant Vice President at Maxpro Ventures, leading investment activities and managing post-investment operations [4] - Previously, she was an Investment Manager at Diamond Biofund, where she oversaw multiple investments and contributed to the fund's IPO in 2023 [5] - Dr. Huang has a strong scientific background, with research published in notable journals and awards for her doctoral work [6] Company Overview - Apollomics Inc. focuses on developing oncology therapies, with its lead program being vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer [7]

Core Points - Apollomics Inc. has successfully appealed a delisting notice from Nasdaq and will continue to be listed on the Nasdaq Stock Market [1] - The company is focused on developing therapies for resistant and refractory cancers, with its lead candidate being vebreltinib (APL-101), a selective c-Met inhibitor [2] Group 1 - Apollomics Inc. is a late-stage clinical biopharmaceutical company based in California, dedicated to developing various candidate oncology drugs [1] - The Nasdaq listing qualification department has determined that Apollomics meets the requirements for continued listing, leading to the cancellation of the scheduled appeal hearing [1] - The company's securities will continue to trade on the Nasdaq Stock Market [1] Group 2 - Apollomics is currently conducting Phase II multi-cohort clinical trials for vebreltinib, targeting non-small cell lung cancer and other advanced tumors with c-Met gene alterations [2] - The company aims to explore and develop cancer therapies that leverage the human immune system and target specific molecular pathways [2]

Core Points - Apollomics Inc. has successfully appealed a delisting notification from Nasdaq, resulting in the cancellation of the scheduled hearing and the continuation of its listing on the Nasdaq Stock Market [1] - The company is focused on developing oncology therapies, particularly its lead program vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer [2] Company Overview - Apollomics Inc. is a clinical-stage biopharmaceutical company based in California, specializing in oncology drug development aimed at treatment-resistant cancers [2] - The lead drug candidate, vebreltinib, is currently undergoing a Phase 2 multicohort clinical trial in the United States and other countries [2]

Core Viewpoint - Apollomics Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly for patients with limited treatment options, and is currently advancing its lead candidate APL-101 (vebreltinib) through global clinical trials [1][3]. Group 1: Company Overview - Apollomics has 9 drug candidates in its pipeline, with 6 in clinical development targeting challenging cancers such as lung cancer and brain cancer [1]. - The company employs a strategy that combines targeted therapies, immuno-oncology, and innovative mechanisms of action to overcome resistance and achieve clinically meaningful efficacy [1]. Group 2: Recent Developments - On August 28, 2025, Apollomics announced plans to terminate all clinical trial activities related to APL-101 due to financial issues and sought shareholder approval for liquidation [2]. - Following a PIPE investment of $4.1 million on September 3, 2025, the company appointed a new board and management team, including Howard Chen as CEO and Alex Chen as COO [2]. Group 3: Clinical Trials and Future Plans - After securing additional funding and a new management team, Apollomics canceled its liquidation plans and will continue its existing operations, including the global development of APL-101 [3]. - The company is committed to completing the SPARTA clinical trials for APL-101, which are crucial for maximizing its therapeutic potential across various tumor types and supporting regulatory submissions in major markets [4]. - Apollomics plans to leverage its partnerships in China to advance regulatory submissions for APL-101 in emerging markets outside of Southeast Asia and the Middle East [4]. Group 4: Workforce and Operations - Apollomics currently has 12 full-time employees, with plans to increase the workforce to 15 by October 31, 2025, while also reducing staff in mainland China and reallocating resources to the U.S. and Taiwan [4].

Core Points - Trading in Apollomics Inc. Class A ordinary shares and warrants will resume on October 15, 2025, at 9:00 a.m. and 9:05 a.m. Eastern Time respectively [1] - Trading was previously halted on September 17, 2025, at 2:37:17 p.m. Eastern Time [1] Company Information - Apollomics Inc. is listed on the Nasdaq Stock Market under the symbols APLM for Class A ordinary shares and APLMW for warrants [1] - For further information, stakeholders are encouraged to contact the company directly or check the Nasdaq website [2]

Core Insights - Apollomics Inc. is a clinical-stage biotechnology company focused on developing innovative oncology therapies, with a pipeline of nine product candidates across 11 programs, including six in clinical development [2] - The company has reversed its plans to wind up operations after securing $4.1 million in PIPE investments and appointing a new management team [4][5] - Apollomics is committed to advancing the global development of APL-101 (vebreltinib) and continuing its clinical trials, particularly the SPARTA trial [5][6] Company Overview - Apollomics is dedicated to transforming cancer treatment for patients with limited options, targeting challenging cancers such as lung and brain cancer [2] - The company employs a strategic approach that includes targeted therapies and immuno-oncology to enhance clinical outcomes [2] Recent Developments - On August 28, 2025, Apollomics announced plans to discontinue clinical trials for APL-101 due to financial concerns, but this decision was reversed following new funding [3][5] - The new management team, led by CEO Howard Chen, has initiated communication with clinical research organizations and licensing partners to ensure continuity in operations and trials [5] Clinical Trials and Future Plans - Apollomics is actively conducting a global Phase 2 trial of APL-101, which has shown positive results in trials involving over 280 patients [2][5] - The company aims to leverage existing approvals for APL-101 in China to pursue regulatory submissions in other regions, including Southeast Asia and the Middle East [6] Workforce and Operations - Apollomics currently has 12 full-time employees, with plans to increase headcount to 15 by October 31, 2025, while reallocating resources to the U.S. and Taiwan [7]

Group 1 - Trading in Apollomics Inc., Ltd. was halted on September 17, 2025, at 14:37:17 Eastern Time for additional information requested by Nasdaq [1] - The last sale price of Apollomics' ordinary shares was $18.4331, while the warrants were priced at $0.0191 [1] - Trading will remain halted until Apollomics has fully satisfied Nasdaq's request for additional information [1]